Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Succinylcholine versus cisatracurium for seizure duration during electroconvulsive therapy
IRCT2016081229310N1Phase 3Completed
- Sponsor
- Vice Chancellor for Research of Isfahan University of Medical Sciences
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of succinylcholine and cisatracurium in attention deficit hyperactivity disorder (ADHD), anorexia nervosa (AN), intellectual disability (ID) and 7 more (2 arms), sponsored by Vice Chancellor for Research of Isfahan University of Medical Sciences. Primary endpoint: Seizure duration. Started Aug 2016; status: completed.
02
Drugs
succinylcholinecisatracurium
03
Conditions
attention deficit hyperactivity disorder (ADHD)anorexia nervosa (AN)intellectual disability (ID)schizophreniamajor depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT2016081229310N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2016081229310N1.